Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OKYO Pharma Ltd ADR (OKYO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: OKYO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -82.47% | Avg. Invested days 18 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 36.54M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 155193 | Beta -3.36 | 52 Weeks Range 0.81 - 1.74 | Updated Date 03/30/2025 |
52 Weeks Range 0.81 - 1.74 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -291.87% | Return on Equity (TTM) -2968.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 42114068 | Price to Sales(TTM) - |
Enterprise Value 42114068 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.29 | Shares Outstanding 33836300 | Shares Floating 23921260 |
Shares Outstanding 33836300 | Shares Floating 23921260 | ||
Percent Insiders 27.61 | Percent Institutions 2.99 |
Analyst Ratings
Rating 4 | Target Price - | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
OKYO Pharma Ltd ADR
Company Overview
History and Background
OKYO Pharma Ltd ADR is a biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of inflammatory dry eye disease and ocular pain. Founded relatively recently, it has focused on developing innovative treatments for underserved ophthalmology conditions.
Core Business Areas
- Inflammatory Dry Eye Disease: Developing therapies to treat the underlying inflammation associated with dry eye disease.
- Ocular Pain: Developing treatments for pain associated with various ocular conditions.
Leadership and Structure
Information on leadership and specific organizational structure is limited in publicly available data but it is assumed they have standard C-suite executives and a board of directors typical of a publicly traded company.
Top Products and Market Share
Key Offerings
- OK-101: OK-101 is an investigational drug being developed for the treatment of dry eye disease (DED). Market share data is not yet available as it is still in clinical trials. Competitors include Novartis' Xiidra, AbbVie's Restasis, and Sun Pharma's Cequa.
- OK-201: OK-201 is an investigational drug being developed for ocular pain. Market share is not applicable as the drug is still under development. The competitors are also in the same phase.
Market Dynamics
Industry Overview
The ophthalmology market is experiencing growth, driven by an aging population, increased prevalence of chronic diseases like diabetes, and rising awareness of eye health. Dry eye disease is a significant and growing segment.
Positioning
OKYO Pharma is positioned as a developer of novel therapies for ocular diseases, targeting specific unmet needs. Its competitive advantage lies in its innovative drug candidates and potential for improved efficacy and safety profiles compared to existing treatments.
Total Addressable Market (TAM)
The global dry eye disease market is projected to reach billions of dollars. OKYO Pharma aims to capture a share of this market with its pipeline products, particularly OK-101.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting unmet needs
- Focus on a specific therapeutic area (ophthalmology)
- Potential for improved efficacy and safety profiles
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on successful clinical trial outcomes
- Dependence on regulatory approvals
Opportunities
- Growing ophthalmology market
- Increasing prevalence of dry eye disease
- Partnerships with larger pharmaceutical companies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- NVS
- ABBV
- SNY
Competitive Landscape
OKYO Pharma faces intense competition from larger pharmaceutical companies with established products in the ophthalmology market. Its success depends on demonstrating superior efficacy and safety with its novel therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not readily available.
Future Projections: Future growth depends on the successful development and commercialization of its pipeline products. Analyst estimates are not readily available.
Recent Initiatives: Recent initiatives include advancing its lead candidate OK-101 through clinical trials.
Summary
OKYO Pharma Ltd ADR is a developing biopharmaceutical company focused on ophthalmology. The company faces significant risks given its reliance on clinical trial success and regulatory approval. Success depends on securing funding and partnering with larger pharmaceutical companies. Currently, the company needs to prove itself to be a worthwhile contender.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
SNY
Sanofi ADR
SNY
Sanofi ADR
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Financial news sources
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OKYO Pharma Ltd ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-05-17 | CEO & Executive Director Dr. Gary S. Jacob Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://okyopharma.com |
Full time employees 3 | Website https://okyopharma.com | ||
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.